Literature DB >> 18654086

Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.

A C Parrott1, J Lock, A C Conner, C Kissling, J Thome.   

Abstract

BACKGROUND/AIMS: The present study is the first to prospectively compare a group of recreational Ecstasy users when dance clubbing on 3,4-methylenedioxymethamphetamine (MDMA) and when clubbing during abstinence from Ecstasy/MDMA.
METHODS: Twelve normal healthy volunteers (mean age = 23.2 years) were assessed at a Saturday night dance club under self-administered MDMA. On the other weekend they went to the same dance club without taking MDMA (order counterbalanced). Both conditions involved 5 test sessions conducted at similar times: pre-drug baseline, 1 h post-drug clubbing, 2.5 h post-drug clubbing, and 2 and 4 days later. The assessments included body and ambient temperature, physical activity (pedometer), as well as self-ratings for mood state, physical activity, thermal comfort and thirst. Saliva samples were analyzed for MDMA, cortisol and testosterone.
RESULTS: The cortisol levels increased significantly by 800% when dance clubbing on MDMA, while testosterone increased significantly by 75%; neither neuroendocrine measure was altered during abstinence. Saliva analyses confirmed the presence of MDMA when dancing on Ecstasy and its absence when dancing off Ecstasy. The pedometer values and self-rated levels of dancing were similar at both weekends. Hot and cold flushes and feeling hot increased significantly under MDMA. The mean body temperature did not change significantly, although there was a borderline trend for increased values after MDMA. Feelings of happiness and excitement increased under MDMA, although they were not significantly greater than when clubbing during abstinence.
CONCLUSIONS: Neurohormonal release may be an important part of the acute MDMA experience. The large cortisol increase provides further data on the bioenergetic stress model of recreational Ecstasy/MDMA. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18654086      PMCID: PMC3575116          DOI: 10.1159/000147470

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  74 in total

1.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

2.  Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.

Authors:  A C Parrott; T Buchanan; A B Scholey; T Heffernan; J Ling; J Rodgers
Journal:  Hum Psychopharmacol       Date:  2002-08       Impact factor: 1.672

3.  MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.

Authors:  J L Reay; C Hamilton; D O Kennedy; A B Scholey
Journal:  J Psychopharmacol       Date:  2006-05       Impact factor: 4.153

4.  Serum cortisol response to incremental work in experienced and naive subjects.

Authors:  H A Davis; G C Gass; J R Bassett
Journal:  Psychosom Med       Date:  1981-04       Impact factor: 4.312

5.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences.

Authors:  Suzanne L Verheyden; Joanne Hadfield; Tara Calin; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2002-03-06       Impact factor: 4.530

Review 7.  Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

8.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

9.  Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.

Authors:  A C Parrott; J Lasky
Journal:  Psychopharmacology (Berl)       Date:  1998-10       Impact factor: 4.530

10.  Persistent neuropsychological problems after 7 years of abstinence from recreational Ecstasy (MDMA): a case study.

Authors:  K Soar; A C Parrott; H C Fox
Journal:  Psychol Rep       Date:  2004-08
View more
  20 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation.

Authors:  Andrew C Parrott
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

3.  Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.

Authors:  Mark A Wetherell; Catharine Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-11-05       Impact factor: 4.530

4.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

5.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Authors:  Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau
Journal:  Brain       Date:  2010-05-17       Impact factor: 13.501

6.  MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study.

Authors:  Andrew C Parrott; Amy Gibbs; Andrew B Scholey; Rebecca King; Katherine Owens; Phil Swann; Ed Ogden; Con Stough
Journal:  Psychopharmacology (Berl)       Date:  2011-02-12       Impact factor: 4.530

7.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

8.  One-year outcomes of prenatal exposure to MDMA and other recreational drugs.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

Review 9.  Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2009-11-05       Impact factor: 2.328

10.  Glucose and corticosterone changes in developing and adult rats following exposure to (+/-)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2009-09-06       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.